Amneal Receives ANDA Approval for Lacosamide Oral Solution, Accelerating Generic Competition for Vimpat
FDA Confirms ANDA Approval for Generic Lacosamide Oral Solution
ANDA 217596, listed in the FDA CDER database, represents the approval of a generic version of lacosamide oral solution (10 mg/mL). Lacosamide is a third-generation anticonvulsant that selectively enhances the slow inactivation of voltage-gated sodium channels. UCB (Euronext: UCB) initially received FDA approval for Vimpat in 2008. It is indicated for focal-onset seizures and primary generalized tonic-clonic seizures in adults and children aged 4 years and older.
Intensified Generic Competition and Market Restructuring
The generic competition for Vimpat in the United States began in March 2022 with the launch of the first generic tablet by Alembic Pharmaceuticals. Subsequently, more than 33 generic manufacturers, including Amneal Pharmaceuticals (NASDAQ: AMRX), Glenmark, Zydus, Aurobindo Pharma, MSN Laboratories, Indoco Remedies, Hetero Labs, Teva, Sun Pharma, and Breckenridge, submitted ANDAs. In the case of oral solution formulations, Amneal secured the first approval with ANDA 204839 in 2016, and most recently, Indoco Remedies received approval for an ANDA based on its Goa, India facility on January 31, 2026. This ANDA 217596 further exemplifies the intensifying competition in the generic oral solution market.
Declining Sales Trajectory for the Original Vimpat
Vimpat achieved peak annual net sales of approximately EUR 1.9 billion (approximately USD 2.0 billion) in 2022, but sales have declined sharply following the entry of generics. Net sales in the first half of 2024 were EUR 744 million, a decrease compared to the same period last year. UCB has already excluded Vimpat from its growth driver product portfolio and is transitioning its portfolio to new pipeline products such as BIMZELX, RYSTIGGO, and ZILBRYSQ. In November 2024, it completed the sale of its mature neurology business, including Vimpat and Keppra, to CBC Group and Mubadala.
Outlook for the Antiepileptic Drug Market and Generic Price Pressure
The global antiepileptic drug market is estimated at approximately USD 12 billion in 2026, with an expected annual growth rate of 5.1%. The entry of lacosamide generics is expected to reduce the price per unit by 50-70% compared to the branded product, but the decline in price is expected to increase accessibility and drive an increase in prescription volume. Meanwhile, UCB's extended-release lacosamide formulation, approved in 2023, is protected by patents until 2040, which helps to preserve some of the brand's residual value.
Vimpat was a blockbuster antiepileptic drug with annual sales exceeding EUR 1.9 billion, and the submission of more than 33 generic ANDAs indicates that the price competition will intensify, further weakening UCB's neurology sales base. UCB is already shifting its sales mix towards immunology (BIMZELX) and rare diseases (RYSTIGGO, ZILBRYSQ), so investors should monitor the gap between the rate of generic erosion and the timing of revenue replacement from new pipelines. From the perspective of generic manufacturers, Amneal (AMRX), Alembic, and Glenmark are expanding their market share in lacosamide across all formulations (oral solution, tablet, and injection), but with more than 33 companies competing in a red ocean, the margin contribution of individual generic companies will be limited. In the global antiepileptic drug market, which is worth USD 12 billion, lacosamide still accounts for approximately 20% and remains a key molecule, and competition between branded and generic products, focusing on extended-release patents (expiring in 2040), is expected to continue for the next 10 years.
Source: openFDA (api_fda)
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=ANDA217596